Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €11.27 EUR
Change Today +1.06 / 10.39%
Volume 0.0
As of 7:49 AM 05/25/15 All times are local (Market data is delayed by at least 15 minutes).

btg plc (B9M) Snapshot

Open
€10.21
Previous Close
€10.21
Day High
€11.27
Day Low
€10.21
52 Week High
05/25/15 - €11.27
52 Week Low
05/27/14 - €7.05
Market Cap
4.3B
Average Volume 10 Days
80.0
EPS TTM
--
Shares Outstanding
381.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BTG PLC (B9M)

Related News

No related news articles were found.

btg plc (B9M) Related Businessweek News

No Related Businessweek News Found

btg plc (B9M) Details

BTG plc, a specialist healthcare company, develops and commercializes products targeting critical care, cancer, and varicose veins. It operates through three segments: Specialty Pharmaceuticals, Interventional Medicine, and Licensing & Biotechnology. The company markets and sells specialty pharmaceuticals, including CroFab, a treatment for patients bitten by North American pit vipers; DigiFab, a treatment for patients suffering toxicity associated with the use of the heart medicine digoxin; and Voraxaze, a treatment for toxic plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function. It also offers a range of interventional oncology products comprising Bead Block, TheraSphere, LC Bead, and DC Bead used to treat patients with hypervascularized tumors; and EkoSonic Endovascular System for the treatment of patients with severe blood clots, and Varithena polidocanol injectable foam for the treatment for patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system. The company’s products in late-stage development include TheraSphere in Phase 3 clinical trials in hepatocellular carcinoma (HCC) and 2nd line metastatic colorectal cancer (mCRC); Beads in investigator-initiated/registration studies in HCC and 3rd line mCRC; and Uridine triacetate in development with Wellstat Therapeutic Corporation as a treatment for toxicity associated with the use of the chemotherapeutic 5-fluorouracil. The company’s licensing products comprise Zytiga, a treatment for patients with prostate cancer; Two-Part Hip Cup, a prosthetic hip joint replacement licensed to hip-replacement technology manufacturers; and Lemtrada, a treatment for patients with relapsing-remitting multiple sclerosis. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.

Founded in 1948

btg plc (B9M) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 1.0M GBP
Chief Financial Officer, Executive Director a...
Total Annual Compensation: 657.0K GBP
Compensation as of Fiscal Year 2014.

btg plc (B9M) Key Developments

BTG plc Announces Revolens Study Results

BTG plc announced the presentation of top line data showing that REVOLENS, a randomized, controlled trial sponsored by the French Ministry of Health, met its primary endpoint. The results show that the PneumRx endobronchial coil is superior to the standard of care for improving exercise capacity in patients with severe emphysema at 6 months as measured by the 6 minute walk test (6MWT). The results were presented by Professor Gaetan Deslee of the University Hospital of Reims, France at the American Thoracic Society (ATS) International Conference in Denver, Colorado. The REVOLENS study randomized 100 patients with severe emphysema from 10 centres in France. The primary outcome measure was the rate of patients showing an improvement greater than or equal to 54 metres distance in the 6MWT at 6 months. An intention to treat analysis showed that the rate of patients meeting the primary endpoint was superior in the coil group (36%) compared to the standard of care group (18%) (P<0.05). REVOLENS (réduction de volume par voie endobronchique par spirales) was a prospective multicenter randomised controlled superiority trial comparing coil treatment with the standard of care in severe emphysema. The study was funded by the French Ministry of Health under the soutien aux techniques innovantes couteuses (STIC) program, which provides government funding for innovative medical technologies that have been validated by prior clinical studies, with a view toward establishing reimbursement for new devices. Developed by PneumRx, a BTG group company, the endobronchial coil is a minimally invasive device intended to improve exercise capacity, lung function, and quality of life for severe emphysema patients. The device has a CE Mark and has been used in Europe for the treatment of emphysema since 2010. Coil treatment is being studied under an Investigational Device Exemption (IDE) in the United States and is not yet approved for commercial use by the FDA. The RENEW Clinical Study, a Phase III pivotal trial of 315 patients completed enrolment in October of 2014 and a US regulatory submission is planned for 2016.

BTG plc Announces Consolidated Final Earnings Results for the Year Ended March 31, 2015; Provides Guidance for the Fiscal 2016

BTG plc announced consolidated final earnings results for the year ended March 31, 2015. For the year, the company reported revenue was £367.8 million against £290.5 million a year ago. Operating profit was £34.9 million against £27.3 million a year ago. Profit before tax was £26.7 million against £33.3 million a year ago. Profit was £33.6 million against £24.3 million a year ago. Diluted earnings per share were 9.0 pence against 6.7 pence a year ago. Net cash inflow from operating activities was £47.5 million against £48.5 million a year ago. Purchases of intangible assets were £1.4 million against £0.9 million a year ago. Purchases of property, plant and equipment was £9.8 million against £11.6 million a year ago. Underlying earnings was £57.8 million against £51.5 million a year ago. Underlying diluted earnings per share were 15.4 pence against 14.3 pence a year ago. The company anticipates further growth in the current financial year 2016, with revenue expected to be in the range £410 million to £440 million (at an exchange rate of £1:$1.61). As company utilizes losses, the company expected to have a low effective tax rate in the short term. The company predicted effective tax rate in the mid- to high-teens for next year and this will increase in the longer term to an effective tax rates of around 26%.

BTG plc, 2015 Earnings Call, May 19, 2015

BTG plc, 2015 Earnings Call, May 19, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
B9M:GR €11.27 EUR +1.06

B9M Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Merit Medical Systems Inc $20.27 USD -0.37
Pfizer Ltd/India 2,212 INR -12.75
RPX Corp $16.04 USD -0.07
Sirtex Medical Ltd A$27.17 AUD -0.38
Medicines Co/The $27.09 USD -0.39
View Industry Companies
 

Industry Analysis

B9M

Industry Average

Valuation B9M Industry Range
Price/Earnings 84.4x
Price/Sales 7.7x
Price/Book 3.7x
Price/Cash Flow 46.8x
TEV/Sales 7.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BTG PLC, please visit www.btgplc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.